BACKGROUND: Alzheimer's disease (AD) is the leading cause of dementia. Currently, no definitive diagnostic test for AD exists. Cerebrospinal fluid (CSF) concentrations of amyloid beta (Abeta1-42) peptides and total tau proteins (T-tau) may serve as biomarkers for AD. AIM: The objective of this study was to investigate the usefulness of CSF Abeta1-42 and T-tau analyses in the diagnosis of AD with Tunisians. METHODS: We focused on three groups originating from Central Tunisian that matched in age (range 48-85): healthy controls (n = 53), AD patients (n = 93) and non-Alzheimer (nAD) dementia (n = 35) patients. Abeta1-42 and T-tau levels were measured in CSF by sandwich enzyme-linked immunosorbent assay. RESULTS: The ratio of T-tau/Abeta1-42 at baseline yielded a sensitivity of 85.3% for detection of AD and the specificity was 84.8% to differentiate controls and nAD dementia. CONCLUSION: Our findings confirm the use of T-tau/Abeta1-42 ratio in the discrimination of AD patients from all other patients.
BACKGROUND:Alzheimer's disease (AD) is the leading cause of dementia. Currently, no definitive diagnostic test for AD exists. Cerebrospinal fluid (CSF) concentrations of amyloid beta (Abeta1-42) peptides and total tau proteins (T-tau) may serve as biomarkers for AD. AIM: The objective of this study was to investigate the usefulness of CSF Abeta1-42 and T-tau analyses in the diagnosis of AD with Tunisians. METHODS: We focused on three groups originating from Central Tunisian that matched in age (range 48-85): healthy controls (n = 53), ADpatients (n = 93) and non-Alzheimer (nAD) dementia (n = 35) patients. Abeta1-42 and T-tau levels were measured in CSF by sandwich enzyme-linked immunosorbent assay. RESULTS: The ratio of T-tau/Abeta1-42 at baseline yielded a sensitivity of 85.3% for detection of AD and the specificity was 84.8% to differentiate controls and nAD dementia. CONCLUSION: Our findings confirm the use of T-tau/Abeta1-42 ratio in the discrimination of ADpatients from all other patients.
Authors: Andrew P Merluzzi; Cynthia M Carlsson; Sterling C Johnson; Suzanne E Schindler; Sanjay Asthana; Kaj Blennow; Henrik Zetterberg; Barbara B Bendlin Journal: Neurology Date: 2018-06-29 Impact factor: 9.910
Authors: Tessandra Stewart; Min Shi; Aanchal Mehrotra; Patrick Aro; David Soltys; Kathleen F Kerr; Cyrus P Zabetian; Elaine R Peskind; Peggy Taylor; Leslie M Shaw; John Q Trojanowski; Jing Zhang Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Karl Hansson; Rahil Dahlén; Oskar Hansson; Elin Pernevik; Ross Paterson; Jonathan M Schott; Nadia Magdalinou; Henrik Zetterberg; Kaj Blennow; Johan Gobom Journal: Clin Mass Spectrom Date: 2019-07-15
Authors: Barbara B Bendlin; Cynthia M Carlsson; Sterling C Johnson; Henrik Zetterberg; Kaj Blennow; Auriel A Willette; Ozioma C Okonkwo; Aparna Sodhi; Michele L Ries; Alex C Birdsill; Andrew L Alexander; Howard A Rowley; Luigi Puglielli; Sanjay Asthana; Mark A Sager Journal: PLoS One Date: 2012-06-06 Impact factor: 3.240
Authors: Jee Wook Kim; Min Soo Byun; Bo Kyung Sohn; Dahyun Yi; Eun Hyun Seo; Young Min Choe; Shin Gyeom Kim; Hyo Jung Choi; Jun Ho Lee; Ik Seung Chee; Jong Inn Woo; Dong Young Lee Journal: Psychiatry Investig Date: 2017-07-11 Impact factor: 2.505